Literature DB >> 28939349

Animal and model systems for studying cystic fibrosis.

Bradley H Rosen1, Marc Chanson2, Lara R Gawenis3, Jinghua Liu4, Aderonke Sofoluwe2, Alice Zoso2, John F Engelhardt5.   

Abstract

The cystic fibrosis (CF) field is the beneficiary of five species of animal models that lack functional cystic fibrosis transmembrane conductance regulator (CFTR) channel. These models are rapidly informing mechanisms of disease pathogenesis and CFTR function regardless of how faithfully a given organ reproduces the human CF phenotype. New approaches of genetic engineering with RNA-guided nucleases are rapidly expanding both the potential types of models available and the approaches to correct the CFTR defect. The application of new CRISPR/Cas9 genome editing techniques are similarly increasing capabilities for in vitro modeling of CFTR functions in cell lines and primary cells using air-liquid interface cultures and organoids. Gene editing of CFTR mutations in somatic stem cells and induced pluripotent stem cells is also transforming gene therapy approaches for CF. This short review evaluates several areas that are key to building animal and cell systems capable of modeling CF disease and testing potential treatments.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal models; CF lung disease; Cellular systems; Gene editing; Pancreatic disease

Mesh:

Substances:

Year:  2017        PMID: 28939349      PMCID: PMC5828943          DOI: 10.1016/j.jcf.2017.09.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  82 in total

1.  Repurposing tromethamine as inhaled therapy to treat CF airway disease.

Authors:  Mahmoud H Abou Alaiwa; Janice L Launspach; Kelsey A Sheets; Jade A Rivera; Nicholas D Gansemer; Peter J Taft; Peter S Thorne; Michael J Welsh; David A Stoltz; Joseph Zabner
Journal:  JCI Insight       Date:  2016-06-02

2.  Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.

Authors:  H Scher; W P Bishop; P B McCray
Journal:  Ann Pharmacother       Date:  1997-09       Impact factor: 3.154

3.  Rapid induction of B-cell lymphomas in mice carrying a human IgH/c-mycYAC.

Authors:  C Bützler; X Zou; A V Popov; M Brüggemann
Journal:  Oncogene       Date:  1997-03-20       Impact factor: 9.867

4.  Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathways.

Authors:  Maisam Abu-El-Haija; Shyam Ramachandran; David K Meyerholz; Marwa Abu-El-Haija; Michelle Griffin; Radhamma L Giriyappa; David A Stoltz; Michael J Welsh; Paul B McCray; Aliye Uc
Journal:  Am J Pathol       Date:  2012-06-08       Impact factor: 4.307

5.  Epidemiology of liver disease in cystic fibrosis: a longitudinal study.

Authors:  Thierry Lamireau; Sylvie Monnereau; Steven Martin; Jacques-Edouard Marcotte; Maria Winnock; Fernando Alvarez
Journal:  J Hepatol       Date:  2004-12       Impact factor: 25.083

6.  Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes.

Authors:  Sebastiano A Musumeci; Giuseppe Calabrese; Carmela M Bonaccorso; Simona D'Antoni; Judith R Brouwer; Cathy E Bakker; Maurizio Elia; Raffaele Ferri; David L Nelson; Ben A Oostra; Maria Vincenza Catania
Journal:  Exp Neurol       Date:  2006-09-27       Impact factor: 5.330

7.  CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes.

Authors:  Benjamin Steines; David D Dickey; Jamie Bergen; Katherine Jda Excoffon; John R Weinstein; Xiaopeng Li; Ziying Yan; Mahmoud H Abou Alaiwa; Viral S Shah; Drake C Bouzek; Linda S Powers; Nicholas D Gansemer; Lynda S Ostedgaard; John F Engelhardt; David A Stoltz; Michael J Welsh; Patrick L Sinn; David V Schaffer; Joseph Zabner
Journal:  JCI Insight       Date:  2016-09-08

8.  New cerebellar phenotypes in YAC transgenic mouse in vivo library of human Down syndrome critical region-1.

Authors:  Mohammed Rachidi; Carmela Lopes; Catherine Vayssettes; Desmond J Smith; Edward M Rubin; Jean-Maurice Delabar
Journal:  Biochem Biophys Res Commun       Date:  2007-10-16       Impact factor: 3.575

9.  Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass.

Authors:  Aliye Uc; Alicia K Olivier; Michelle A Griffin; David K Meyerholz; Jianrong Yao; Maisam Abu-El-Haija; Katherine M Buchanan; Oriana G Vanegas Calderón; Marwa Abu-El-Haija; Alejandro A Pezzulo; Leah R Reznikov; Mark J Hoegger; Michael V Rector; Lynda S Ostedgaard; Peter J Taft; Nick D Gansemer; Paula S Ludwig; Emma E Hornick; David A Stoltz; Katie L Ode; Michael J Welsh; John F Engelhardt; Andrew W Norris
Journal:  Clin Sci (Lond)       Date:  2015-01       Impact factor: 6.124

10.  Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats.

Authors:  Katherine L Tuggle; Susan E Birket; Xiaoxia Cui; Jeong Hong; Joe Warren; Lara Reid; Andre Chambers; Diana Ji; Kevin Gamber; Kengyeh K Chu; Guillermo Tearney; Li Ping Tang; James A Fortenberry; Ming Du; Joan M Cadillac; David M Bedwell; Steven M Rowe; Eric J Sorscher; Michelle V Fanucchi
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

View more
  31 in total

1.  Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.

Authors:  Michael D Kim; Nathalie Baumlin; Makoto Yoshida; Deepika Polineni; Sebastian F Salathe; Joseph K David; Charles A Peloquin; Adam Wanner; John S Dennis; Juliette Sailland; Philip Whitney; Frank T Horrigan; Juan R Sabater; William M Abraham; Matthias Salathe
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

2.  Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice.

Authors:  Birgitta Strandvik; Wanda K O Neal; Mohamed A Ali; Ulf Hammar
Journal:  Exp Biol Med (Maywood)       Date:  2018-03

Review 3.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

4.  Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.

Authors:  Susan E Birket; Joy M Davis; Courtney M Fernandez-Petty; Alexander G Henderson; Ashley M Oden; LiPing Tang; Hui Wen; Jeong Hong; Lianwu Fu; Andre Chambers; Alvin Fields; Gojun Zhao; Guillermo J Tearney; Eric J Sorscher; Steven M Rowe
Journal:  Am J Respir Crit Care Med       Date:  2020-11-01       Impact factor: 21.405

Review 5.  Animal models of cystic fibrosis in the era of highly effective modulator therapies.

Authors:  Barbara R Grubb; Alessandra Livraghi-Butrico
Journal:  Curr Opin Pharmacol       Date:  2022-05-13       Impact factor: 4.768

Review 6.  Animal models for cystic fibrosis liver disease (CFLD).

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Massimiliano Cadamuro; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-07-30       Impact factor: 5.187

7.  Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions.

Authors:  Domizia Baldassi; Bettina Gabold; Olivia Merkel
Journal:  Adv Nanobiomed Res       Date:  2021-05-06

Review 8.  The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.

Authors:  Ren-Jay Shei; Jacelyn E Peabody; Niroop Kaza; Steven M Rowe
Journal:  Curr Opin Pharmacol       Date:  2018-10-16       Impact factor: 5.547

Review 9.  On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis.

Authors:  Marjolein Ensinck; Angélique Mottais; Claire Detry; Teresinha Leal; Marianne S Carlon
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

Review 10.  Advances in gene therapy for cystic fibrosis lung disease.

Authors:  Ziying Yan; Paul B McCray; John F Engelhardt
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.